New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
Jayne Hornung
Advertisement
Chief clinical officer, MMIT (Managed Markets Insight & Technology).
Articles by Jayne Hornung
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
2
Who Pays for Tariff Driven Input Cost Increases?
3
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
4
The Shift Towards Globally Sourced Innovation
5